论文部分内容阅读
目的探讨孟鲁司特钠联合布地奈德治疗咳嗽变异性哮喘患儿的临床效果。方法选取2015年3月至2016年7月辽宁省营口市中医院收治的80例咳嗽变异性哮喘患儿作为研究对象,按随机数字表法将其分为对照组40例(布地奈德治疗)和研究组40例(孟鲁司特钠+布地奈德治疗),比较两组患儿临床疗效、症状改善时间及治疗时间、肺功能。结果研究组患儿治疗的总有效率为92.5%,明显高于对照组的77.5%,差异有统计学意义(P<0.05);研究组患儿咳嗽缓解和消失时间、总治疗时间均明显短于对照组,差异均有统计学意义(均P<0.05);治疗后,研究组患儿的第一秒钟用力呼气量与用力肺活量的百分比(FEV1/FVC)、呼气峰流速(PEF)、FEV1均明显高于对照组,差异均有统计学意义(均P<0.05)。结论临床治疗小儿咳嗽变异性哮喘疾病可考虑将孟鲁斯特和布地奈德联合使用,疗效突出,安全可靠,可有效改善肺功能。
Objective To investigate the clinical effect of combination of montelukast and budesonide in the treatment of children with cough variant asthma. Methods Eighty children with cough variant asthma admitted from Yingkou Municipal Hospital of Traditional Chinese Medicine from March 2015 to July 2016 in Liaoning Province were enrolled in this study. According to random number table, they were divided into control group 40 cases (budesonide treatment) And study group 40 cases (montelukast sodium + budesonide treatment). The clinical curative effect, symptom improvement time, treatment time and lung function of the two groups were compared. Results The total effective rate of treatment group was 92.5%, which was significantly higher than that of the control group (77.5%) (P <0.05). The relieving and disappearing time of cough and the total treatment time of study group were significantly shorter (P <0.05). After treatment, the FEV1 / FVC and FEV1 of the first-second forced expiratory volume and forced expiratory volume (PEF) in the study group were significantly higher than those in the control group ), FEV1 were significantly higher than the control group, the differences were statistically significant (P <0.05). Conclusion Clinical treatment of children with cough variant asthma can be considered montelukast and budesonide combination of outstanding efficacy, safety and reliability, can effectively improve lung function.